ConductScience.org, home

Paper20175033

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Lencioni R and 1 other. Semin Liver Dis, 2010. Cited by 3,769 papers, by iCite.

Cite this record

ConductScience Library. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Papers, record 20175033. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20175033

Download JSON
Disease
hepatocellular carcinoma478 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
PubMed
Journal
Semin Liver Dis
PubMed
Year
2010
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
3,769
iCite
Relative citation ratio, by iCite
112
iCite
Revised in PubMed
2025-07-19
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lencioni RRiccardo
2Llovet JMJosep M

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, HepatocellularMajor topic
Fluorodeoxyglucose F18Major topic
Liver NeoplasmsMajor topic
Practice Guidelines as TopicMajor topic
Clinical Trials as Topic
Diagnostic Imaging
Drug Delivery Systems
Humans
Magnetic Resonance Imaging
Neoplasm Staging
Outcome Assessment, Health Care
Positron-Emission Tomography
Prognosis
Radiopharmaceuticals
Tomography, X-Ray Computed
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 DK076986NIDDK NIH HHSUnited StatesR01DK076986PubMed and NIH
1R01DK076986-01NIDDK NIH HHSUnited StatesR01DK076986PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials12

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01387503Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through DownstagingBackgroundClinicalTrials.gov
NCT02311205Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)BackgroundClinicalTrials.gov
NCT02630108TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular CarcinomaResultsClinicalTrials.gov
NCT02729506Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular CarcinomaResultsClinicalTrials.gov
NCT03248375Impact of Y90 Radiation Segmentectomy on HCCBackgroundClinicalTrials.gov
NCT04048317Effectiveness of Drug Eluting TACE in Primary HCCBackgroundClinicalTrials.gov
NCT04803019Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular CarcinomaBackgroundClinicalTrials.gov
NCT05171335Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma PatientsBackgroundClinicalTrials.gov
NCT05185505Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan CriteriaBackgroundClinicalTrials.gov
NCT05435014T-ACE Oil by TAE/TACE in Patients With Hepatocellular CarcinomaBackgroundClinicalTrials.gov
NCT05776875Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCCBackgroundClinicalTrials.gov
NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialBackgroundClinicalTrials.gov

Download CSV of trials

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
219097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
37459811Reporting results of cancer treatment.Cancer1981https://conductscience.org/library/papers/7459811PubMed
412540794Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival.Hepatology2003https://conductscience.org/library/papers/12540794PubMed
519095437Individual patient data analysis to assess modifications to the RECIST criteria.Eur J Cancer2009https://conductscience.org/library/papers/19095437PubMed
616298014Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.J Hepatol2006https://conductscience.org/library/papers/16298014PubMed
719117042Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?Cancer2009https://conductscience.org/library/papers/19117042PubMed
810655437
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
J Natl Cancer Inst2000https://conductscience.org/library/papers/10655437PubMed
918477802Design and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst2008https://conductscience.org/library/papers/18477802PubMed
1016250051Management of hepatocellular carcinoma.Hepatology2005https://conductscience.org/library/papers/16250051PubMed
1111592607Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.J Hepatol2001https://conductscience.org/library/papers/11592607PubMed
1214667750Hepatocellular carcinoma.Lancet2003https://conductscience.org/library/papers/14667750PubMed
1314512891MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation.Hepatology2003https://conductscience.org/library/papers/14512891PubMed

Download CSV of references

Cited by2,373

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,769 citations.

PMIDTitleJournalYearIn PapersSource
42984496Muscle strength and muscle mass phenotypes and survival in unresectable hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy-based combination therapy.Front Oncol2026https://conductscience.org/library/papers/42984496PubMed
42982861FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study.Nat Commun2026https://conductscience.org/library/papers/42982861PubMed
42973518
Early discordance between alpha-fetoprotein response and albumin-bilirubin deterioration refines response assessment in unresectable hepatocellular carcinoma receiving first-line immune-combination therapy: a real-world landmark cohort study.
Front Oncol2026https://conductscience.org/library/papers/42973518PubMed
42968863Efficacy and Safety of Sequential Radiotherapy and Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Single-Center PSM Retrospective Cohort Study.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42968863PubMed
42967182Conversion Surgery After HAIC-Based Combination Therapy with Targeted Therapy and Immune Checkpoint Inhibitors for Initially Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study.J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42967182PubMed
42967027Enhanced Efficacy of Thalidomide-Based Cocktail With Transarterial Chemoembolization in the Management of Unresectable Hepatocellular Carcinoma: A Multi-Center Cohort Study.MedComm (2020)2026https://conductscience.org/library/papers/42967027PubMed
42960031Sequential surgery after conversion therapy for advanced hepatocellular carcinoma: Evidence, controversies, and perspectives.ILIVER2026https://conductscience.org/library/papers/42960031PubMed
42953006CT habitat and peritumoral radiomics for predicting progression after repeat TACE in hepatocellular carcinoma: a multicenter study.Front Pharmacol2026https://conductscience.org/library/papers/42953006PubMed
42948561von Willebrand Factor and ADAMTS13 Predict Therapeutic Efficacy and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Atezolizumab-Bevacizumab.JGH Open2026https://conductscience.org/library/papers/42948561PubMed
42938898Baseline Host Biomarkers and Six-Month Sustained Drug-Free Status After Atezolizumab-Bevacizumab for Hepatocellular Carcinoma: Exploratory Clinical Stratification Using PAN-DF Score.Cancers (Basel)2026https://conductscience.org/library/papers/42938898PubMed
42938852BCIW-Net: Boundary-Conditioned Adaptive CT Windowing for Hepatocellular Carcinoma Segmentation.Cancers (Basel)2026https://conductscience.org/library/papers/42938852PubMed
42938169Treatment-Stratified Immune-Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy.Diagnostics (Basel)2026https://conductscience.org/library/papers/42938169PubMed
42936717
Salvage Yttrium-90 Transarterial Radioembolization Combined with Second-Line Molecular Targeted Agents and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Progressing After TACE-Based Combination Therapy: A Single-Center Real-World Study.
J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42936717PubMed
42924150Drug-eluting bead transarterial chemoembolization with immunotherapy and targeted therapy for advanced clear cell renal cell carcinoma: A case report.Oncol Lett2026https://conductscience.org/library/papers/42924150PubMed
42921173
The Efficacy and Safety of Combined Locoregional and Systemic Therapy versus Systemic Therapy Alone in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: A Multicenter Real-World Retrospective Cohort Study.
J Hepatocell Carcinoma2026https://conductscience.org/library/papers/42921173PubMed
42910203Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology.Liver Cancer2026https://conductscience.org/library/papers/42910203PubMed
42909267Liver-resident cellular determinants of oncolytic virotherapy in hepatocellular carcinoma: viral susceptibility and spatial immune remodeling.Front Cell Dev Biol2026https://conductscience.org/library/papers/42909267PubMed
42908779Low CT-derived vertebral attenuation as a prognostic factor in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.Front Oncol2026https://conductscience.org/library/papers/42908779PubMed
42908554LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.Front Oncol2026https://conductscience.org/library/papers/42908554PubMed
42895551Sequential transarterial radioembolization and atezolizumab plus bevacizumab improves survival in advanced hepatocellular carcinoma.Eur Radiol2026https://conductscience.org/library/papers/42895551PubMed

See all 2,373 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ETHIODIZED OILCHEMBL1201458Results1https://conductscience.org/library/drugs/CHEMBL1201458

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20175033

GET https://conductscience.org/api/papers/v1/20175033/cited_by?page=2